The new LifeArc Gene Therapy Innovation Fund is a £5m annual fund for gene therapy technologies – and includes support from the world-class network of Innovation Hubs for Gene Therapies.
The fund provides grants to academic researchers working to advance new gene therapy technologies from preclinical research through to early clinical studies. Successful projects will be awarded additional funding to enable them to use the manufacturing capabilities of the Innovation Hubs for Gene Therapies.
The £5m Gene Therapy Innovation Fund aims to advance promising viral therapy technologies for people living with a genetic condition, including rare diseases and those where treatment options are currently limited.
The funding will support the development of potential gene therapies from preclinical through to early exploratory trials — including the manufacturing and clinical costs for developing these further. This unique package allows the technologies to remain in academia for optimal development and from where it is more likely to attract follow-on investment.
The next deadlines for applications are 5 May 2023 and
15 September 2023.
Projects must be led by research-active professionals based at UK universities, hospitals or research institutes. We encourage applications involving a collaboration with other academic partners or industry and where the collaboration agreements are in place or planned. Lead applicants may only submit one application per round.
APPLY FOR THE GENE THERAPY INNOVATION FUND
The funding will support the academic-led, advanced therapy proposal through the project design stage using the services of one of the Innovation Hubs.
Stage 1: Review preliminary application and Hub allocation
We will review preliminary applications that are within remit and outline the planned approach and supportive data. The project will be matched to an Innovation Hub for further development.
Stage 2: Refine the proposed technology and submit full application
LifeArc and the allocated Innovation Hub will review the application’s scientific, regulatory and technology basis, and also identify any gaps to be addressed before submitting a full application. In a process that will be tailored to the needs of the respective application, we will assist you to address any issues and refine the technology in preparation for your submission.
Stage 3: Conduct due diligence
Once you have submitted the full proposal, we will conduct due diligence on the information provided, and gain external peer review, sharing comments back with you to address, if you wish.
Stage 4: Peer review and funding decision
The funding panel will consider the submitted application and all related peer review information and make the final decision. The panel makes these project decisions twice a year, usually in December and June.
Stage 5: Funding agreement
If the panel agrees to fund the project, we will formalise the funding agreements and project milestones.
Stage 6: Milestone report
LifeArc and the allocated Hub continue to work with the awardee and support and manage the project to meet the pre-agreed milestones.
Stage 7: Project end and final report
The final results of the project are reviewed, and the next steps and possible further assistance discussed with the network of Innovation Hubs for Gene Therapy and LifeArc.
The allocation committee is formed of scientific and business development representatives from across the three Hubs, along with a LifeArc representative. The allocation committee will recommend the most appropriate Hub to support the project matching the project’s manufacturing needs to their individual capabilities. You may indicate a preferred Hub if you wish, but one will be assigned to you if you do not specify a preference in the preliminary application.
All applications will be reviewed by our funding panel, consisting of external expert partners from academia, charities and industry. Read about our funding panel members here.
The next deadlines for applications are:
Completed application forms will be reviewed by the allocation panel and successful applications will be matched with an Innovation Hub, with an aim of the proposal being reviewed and developed for full application submission.
Submission of a full application to the LifeArc Gene Therapy Innovation Fund is by invitation only, and with the support of the allocated Innovation Hub.
The funding panel reviews full applications and makes funding decisions twice a year, in June and December. The closing date for completed, full applications will be in March and August each year.
The initial collaboration work-up with the Hubs is covered by this fund. Using their expertise, the allocated Hub will assist the academic applicant to deliver on a development plan with a view to the proposed project being suitably ready to the submission of a full application. The allocated Hub will decide when the project is ready for full application submission.
Academics need to submit a completed preliminary form for initial review. A funding panel, made up of translational scientists and clinicians from academia and industry evaluate proposals and, if they are within the funding criteria, will allocate the project to an innovation Hub for further support.
Using the expertise of the allocated Hub, the wider network and LifeArc, a thorough diligence will be performed (i.e., scientific, regulatory and technology) to identify gaps, which you will need to address in preparation for the submission of a full application. LifeArc will support you throughout this process, which is tailored to each application.
Awardees are required to provide a quarterly update report from the project commencement date, alongside agreed milestone dates.
Co-funded applications are welcome with the appropriate collaboration terms outlined. Funding support will be awarded to the academic institution.
LifeArc will not ask for any financial return or intellectual property from projects supported by this grant, allowing researchers to focus purely on delivering a result that benefits patients.
We will provide feedback with the funding decision. Any invitation to reapply will be made at the funding panel’s discretion.